Heart and Blood Diseases

All Conditions

Neoplasms

Skin and Connective Tissue Diseases

Blood and Lymph Conditions

Immune System Diseases

Symptoms and General Pathology

Substance Related Disorders

Wounds and Injuries

Rare Diseases

Heart Failure

Breast Neoplasms

Lymphoma

Cardiotoxicity

Heart Diseases

Drug-Related Side Effects and Adverse Reactions

Chemically-Induced Disorders

Radiation Injuries

Lymphosarcoma

Antihypertensive Agents

All Drugs and Chemicals

Dermatologic Agents

Valsartan

Coal Tar

Sacubitril and valsartan sodium hydrate drug combination

Sacubitril/Valsartan (25/80) mg twice a day for 1 year

With the value of GLS function via echocardiography study decreased \>15%, No intervention

Prevention therapy

Rescue therapy

Ping-Yen Liu, PhD.

Pei-Tien Hsu

Ping-Yen Liu, PhD

Ping-Yen Liu, MD, PhD

The investigators use the cancer registration system of National Cheng Kung University Hospital to timely screen and evaluate those patients having breast cancer or lymphoma to enroll patients to participate in this clinical trial. The investigators planned an earlier initiation of Sacubitril/Valsartan treatment on breast cancer and lymphoma patients before the chemotherapy, and starting therapeutic intervention by Sacubitril/Valsartan once the heart damage sign appeared via novel echocardiography. The investigators aim to assess the protective and therapeutic benefit of cardioprotective drugs on the cardiotoxicity of anti-cancer therapy.

The investigators use the cancer registration system of National Cheng Kung University Hospital to timely screen and evaluate those patients having breast cancer or lymphoma to enroll patients to participate in this clinical trial. Also, the Patient Recruitment System support to complete the patients' database. The investigators cooperate with other hospitals in South Taiwan to carry on an early phase clinical trial, named "Strategy by novel anti-heart failure therapy on early phase Cancer Therapeutics-Related Cardiac Dysfunction (CTRCD) patients" focusing on the either preventive strategy to earlier initiation of Sacubitril/Valsartan treatment on breast cancer and lymphoma patients before the chemotherapy, and starting therapeutic intervention by Sacubitril/Valsartan once the heart damage sign appeared via novel echocardiography, and collect clinical and genetic information from the enrolled patients. These patients randomized into 2 groups: cardioprotective drug vs. placebo. The regular assessment of cardiac function is as following: baseline (prior to anti-cancer treatment) and every 3 months. Thereafter. The investigators aim to assess the protective and/or therapeutic benefit of cardioprotective drugs on the cardiotoxicity of anti-cancer therapy.

Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction

Strategy Therapy on Early Phase Cancer Therapeutics-Related Cardiac Dysfunction Patients

Left ventricular global peak systolic longitudinal strain by cardiac echo

Left ventricular ejection fraction by cardiac echo

admission due to heart function deterioration

Cardiac biomarkers (NT-proBNP and hs-cTnT) changes

National Cheng-Kung University Hospital

Doctor/Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction	NCT05892146	Chemotherapeuti... Cardiotoxicity Heart Failure Breast Cancer Lymphoma	Prevention ther... Rescue therapy	20 Years - 65 Years	National Cheng-Kung University Hospital
Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction	NCT05892146	Chemotherapeuti... Cardiotoxicity Heart Failure Breast Cancer Lymphoma	Prevention ther... Rescue therapy	20 Years - 65 Years	National Cheng-Kung University Hospital
Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction	NCT05892146	Chemotherapeuti... Cardiotoxicity Heart Failure Breast Cancer Lymphoma	Prevention ther... Rescue therapy	20 Years - 65 Years	National Cheng-Kung University Hospital

Spots Global Cancer Trial Database for prevention therapy